Additional file 5 of Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer

Additional file 5: Table S2. Pharmacodynamic changes in protein levels in acquired resistant cells versus parental cells. RPPA data (norm_Log2 values) restricted to the proteins with a > 0.25 or < − 0.25 difference in log 2 expression in EFM19-PR resistant cells compared to EFM19 parental cells.补充文件5：表S2。获得性耐药细胞与亲本细胞间蛋白质水平的药效学变化。本数据为反向蛋白阵列（RPPA）的标准化log2（norm_Log2）数值，仅保留EFM19-PR耐药细胞相较于EFM19亲本细胞，其log2表达量差异大于0.25或小于-0.25的蛋白质。